These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 21088111)

  • 1. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
    Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
    Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
    Yang SH; Chang SY; Andres DA; Spielmann HP; Young SG; Fong LG
    J Lipid Res; 2010 Feb; 51(2):400-5. PubMed ID: 19965595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome.
    Davies BS; Yang SH; Farber E; Lee R; Buck SB; Andres DA; Spielmann HP; Agnew BJ; Tamanoi F; Fong LG; Young SG
    J Lipid Res; 2009 Jan; 50(1):126-34. PubMed ID: 18757838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
    Wang Y; Ostlund C; Worman HJ
    Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prelamin A farnesylation and progeroid syndromes.
    Young SG; Meta M; Yang SH; Fong LG
    J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele.
    Yang SH; Qiao X; Farber E; Chang SY; Fong LG; Young SG
    J Biol Chem; 2008 Mar; 283(11):7094-9. PubMed ID: 18178963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated.
    Yang SH; Andres DA; Spielmann HP; Young SG; Fong LG
    J Clin Invest; 2008 Oct; 118(10):3291-300. PubMed ID: 18769635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
    Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and pharmacological modulation of lamin A farnesylation determines its function and turnover.
    Foo MXR; Ong PF; Yap ZX; Maric M; Bong CJS; Dröge P; Burke B; Dreesen O
    Aging Cell; 2024 May; 23(5):e14105. PubMed ID: 38504487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.
    Davies BS; Barnes RH; Tu Y; Ren S; Andres DA; Spielmann HP; Lammerding J; Wang Y; Young SG; Fong LG
    Hum Mol Genet; 2010 Jul; 19(13):2682-94. PubMed ID: 20421363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
    Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
    Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear localization signal deletion mutants of lamin A and progerin reveal insights into lamin A processing and emerin targeting.
    Wu D; Flannery AR; Cai H; Ko E; Cao K
    Nucleus; 2014; 5(1):66-74. PubMed ID: 24637396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
    J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes.
    Moulson CL; Fong LG; Gardner JM; Farber EA; Go G; Passariello A; Grange DK; Young SG; Miner JH
    Hum Mutat; 2007 Sep; 28(9):882-9. PubMed ID: 17469202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin.
    Wang Y; Panteleyev AA; Owens DM; Djabali K; Stewart CL; Worman HJ
    Hum Mol Genet; 2008 Aug; 17(15):2357-69. PubMed ID: 18442998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
    Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.